Human Material Transfer Agreement (Hmta) Sample Contracts
Human Material Transfer Agreement (HMTA)Human Material Transfer Agreement (Hmta) • December 8th, 2022
Certain CIMACs (collectively “Recipient CIMACs”) will be receiving the biospecimens as specified in Appendix A of this Agreement; and the data related to the biospecimens will be provided to Dana-Farber Cancer Institute, Inc. (the “CIDC”), and may be accessed, as described below, by Leland Stanford Junior University, the University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Inc., and the Icahn School of Medicine at Mount Sinai (“the CIMACs”). The CIMACs and CIDC are jointly the “Recipients”. Each Recipient and the Provider is hereafter individually referred to as a “Party” and jointly as the “Parties”. This Agreement is effective as of the date of last signature of an authorized representative of a Party below (“Effective Date”).
Standard Contracts
Cancer Immune Monitoring and Analysis Centers - Cancer Immunologic Data Commons (CIMAC-CIDC) Human Material Transfer Agreement (HMTA) Version: February 27, 2019Human Material Transfer Agreement (Hmta) • March 18th, 2019
This Human Material Transfer Agreement (“Agreement”) will be effective on the date of last authorized signature below, (“Effective Date”). The purpose of this Agreement is to transfer NCI-sponsored clinical trial biospecimens and associated data from [Provider Name], hereinafter referred to as “Provider”, to Dana-Farber Cancer Institute, Inc., Leland Stanford Junior University, the University of Texas MD Anderson Cancer Center, and the Icahn School of Medicine at Mount Sinai (each a “CIMAC”); and Dana-Farber Cancer Institute, Inc. (the “CIDC”) who will receive the data related to the biospecimens, (jointly the “Recipients”). Each Recipient and the Provider is hereafter individually referred to as a “Party” and jointly as the “Parties”.
